ClinicalTrials.gg
CompletedNCT06294301Updated Dec 15, 2025

A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants

A Phase 1 interventional study of LP-005 Dose 1 (Single) and LP-005 Dose 2 (Single) in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Longbio Pharma. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Longbio Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies in Hemoglobinuria, Paroxysmal with a site in China — 21 open to participants now, 29 under way, 11 of them phase 3. Hemoglobinuria, Paroxysmal · China.

Enrollment
14th of 47
68 · median 40
Started
2023
with 5 others
Phase 1
13 of 51
5 open now
Registered
20th of 51
by date
Lead sponsor
3 of 51
Longbio Pharma

Among the 51 studies in Hemoglobinuria, Paroxysmal with a site in China, this one is the 14th largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2023, is one of 13 in phase 1, and was the 20th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

21 of the 51 studies in Hemoglobinuria, Paroxysmal with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hemoglobinuria, Paroxysmal with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-005 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-005 and Part 2, multiple ascending dose (MAD).

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males or females aged 18 through 50 years
  2. Male subjects with a weight of ≥50 kg, female subjects with a weight of ≥45 kg, and between 19.0 and 26.0 kg/m² (inclusive).
  3. Vaccination: Meningococcal Conjugate Vaccine, Serogroups A, C, W, Y (MPV-ACYW) meningococcal conjugate vaccine and Streptococcus pneumoniae vaccine should be given 14 days or more before randomisation.
  4. Male subjects and their partners or female subjects must agree to use one or more non-pharmaceutical methods (such as total abstinence, condoms, Iuds, partner ligation, etc.) during the trial period and for 6 months after the trial, and do not plan to donate sperm or eggs.
  5. The subjects fully understand the purpose, nature, method and possible adverse reactions of the experiment, and voluntarily participate in the experiment and sign the .
  6. The subjects were able to communicate well with the researchers and complete the study according to the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participants who are or have one of the following underlying diseases: anatomic absence of spleen (including sickle cell disease); congenital complement component deficiencies (complement component 3 and complement component 4).
  2. Any history of Neisseria gonorrhea, meningitis infection, and Guillain-Barré syndrome.
  3. to meningococcal vaccination (previous medical history such as epilepsy or other brain disorders).
  4. Presence or suspicion of active viral, bacterial, fungal, or parasitic infection, including herpes, shingles, or cold sores, within 14 days prior to screening.
  5. History of unexplained recurrent infections, or use of systemic antibiotics within 90 days prior to dosing.
  6. or history of malignancy, except non-melanoma skin cancer cured for more than 3 years.
  7. Positive test (HIV-Ab), positive virus (HBV) test (HBsAg), positive virus (HCV), positive anti-syphilis helix-specific antibodies.
  8. Participation in a clinical trial of any other drug within 3 months prior to screening or within 5 half-lives of other clinical trial drugs (selecting the longer time period).
  9. Women who are pregnant, breastfeeding, or at risk of pregnancy.
  10. Any condition deemed unsuitable for study participation by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Cohort 1: LP-005 Dose 1 (Single)

    Biological: LP-005 Dose 1 (Single)

  • Experimental
    Cohort 2: LP-005 Dose 2 (Single)

    Biological: LP-005 Dose 2 (Single)

  • Experimental
    Cohort 3: LP-005 Dose 3 (Single)

    Biological: LP-005 Dose 3 (Single)

  • Experimental
    Cohort 4: LP-005 Dose 4 (Single)

    Biological: LP-005 Dose 4 (Single)

  • Experimental
    Cohort 5: LP-005 Dose 5 (Single)

    Biological: LP-005 Dose 5 (Single)

  • Experimental
    Cohort 6: LP-005 Dose 6 (Single)

    Biological: LP-005 Dose 6 (Single)

  • Placebo comparator
    Cohort 7: Placebo (Single)

    Biological: Placebo (Single)

  • Experimental
    Cohort 8: LP-005 Dose 7 (Multiple)

    Biological: LP-005 Dose 7 (Multiple)

  • Experimental
    Cohort 9: LP-005 Dose 8 (Multiple)

    Biological: LP-005 Dose 8 (Multiple)

  • Experimental
    Cohort 10: LP-005 Dose 9 (Multiple)

    Biological: LP-005 Dose 9 (Multiple)

  • Placebo comparator
    Cohort 11: Placebo (Multiple)

    Biological: Placebo (Multiple)

Interventions

  • A single dose of LP-005 (Dose 1) was administered intravenously.

  • A single dose of LP-005 (Dose 2) was administered intravenously.

  • A single dose of LP-005 (Dose 3) was administered intravenously.

  • A single dose of LP-005 (Dose 4) was administered intravenously.

  • A single dose of LP-005 (Dose 5) was administered intravenously.

  • A single dose of LP-005 (Dose 6) was administered intravenously.

  • BiologicalPlacebo (Single)

    A single dose of placebo was administered intravenously.

  • LP-005 (Dose 7) was administered multiple times intravenously.

  • LP-005 (Dose 8) was administered multiple times intravenously.

  • LP-005 (Dose 9) was administered multiple times intravenously.

  • BiologicalPlacebo (Multiple)

    Placebo was administered multiple times intravenously.

06

What researchers measure

Primary outcomes

  1. Adverse events

    Number of subjects with treatment-related Treatment Emergent Adverse Events (TEAEs).

    Time frame: Observation for 78 days after administration

Secondary outcomes

  1. Time to peak concentration (Tmax) of LP-005

    The time when the blood drug concentration reaches its peak after a single dose of medication.

    Time frame: Observation for 78 days after administration

  2. Maximum concentration (Cmax) of LP-005

    The maximum concentration of LP-005 in the bloodstream after administration.

    Time frame: Observation for 78 days after administration

  3. Elimination half-life (t1/2) of LP-005

    The time required for the concentration of LP-005 in the bloodstream to decrease by half.

    Time frame: Observation for 78 days after administration

  4. Area under the concentration-time curve (AUC0-t) of LP-005

    The area under the concentration-time curve (AUC) from time zero to the last chosen time point represents the integral of the drug concentration in the bloodstream over the specified duration.

    Time frame: Observation for 78 days after administration

  5. Apparent clearance rate (CL/F) of LP-005

    The ratio of drug clearance to drug concentration, represents the apparent clearance of a drug after administration, adjusted for bioavailability.

    Time frame: Observation for 78 days after administration

  6. Assessment of immunogenicity

    The proportion of anti drug antibody (ADA) positive subjects at different detection time points.

    Time frame: Observation for 78 days after administration

  7. Assessment of complement C5 activity

    Evaluate complement C5 hemolytic activity and serum concentration of C5 changes from baseline at various time points of assessment.

    Time frame: Observation for 78 days after administration

  8. Assessment of complement C3b activity

    Evaluate C3b deposition on red blood cells and serum concentration of C3b changes from baseline at various time points of assessment.

    Time frame: Observation for 78 days after administration

07

Study locations

1 site
  • Shanghai Public Health Clinical Center
    Shanghai, Shanghai Municipality, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Aug 2024, 9 months.

Of 19 phase 1 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2024
First posted
Mar 5, 2024
StartActual
Nov 23, 2023
Primary completionActual
Aug 31, 2024
CompletionActual
Aug 31, 2024
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06294301
Lead sponsor
Longbio Pharma
Responsible party
Sponsor
First posted
Mar 5, 2024
Start date
Nov 23, 2023
Primary completion
Aug 31, 2024
Completion
Aug 31, 2024
Last update
Dec 15, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LP-005

Start the discussion